P011 Final results of the REVISAR study (REcanalization of distal cerebral Vessels In acute Stroke using APERIO®)

<h3>Introduction</h3> REVISAR is a prospective multicenter study on mechanical thrombectomy in distal vessels using the APERIO® (Hybrid (17)) Stentretriever. <h3>Aim of Study</h3> To evaluate the safety and efficacy of the APERIO® (Hybrid(17)) Thrombectomy device in distal artery occlusions in the anterior and posterior circulation. <h3>Methods</h3> Data was collected prospectively from all patients who signed informed consent. Efficacy endpoints were successful recanalization (TICI 2b-3) within 3 passes, no rescue therapy, no sICH and a good outcome at 90 days (mRS≤2). Primary safety endpoints were device- and procedure-related (serious) adverse events (AEs/SAEs) and mortality. Imaging data were evaluated by the centers and a central core lab. Primary inclusion criterion was treatment with the APERIO, the APERIO® Hybrid or APERIO® Hybrid¹⁷. Major exclusion criteria were any contraindication according to IFU and pretreatment mRS of ≥3. <h3>Results</h3> 134 patients were enrolled between 2020 and 2023. Median age was 74, 51% of the patients were female, median NIHSS was 7. There were 83 M2 (62%), 19 M3 (14%), 13 P1/2 (10%), 7 A1-3 (5%) and 12 other occlusions (9%). Successful recanalization (mTICI 2b-3) was achieved in 95.5%. A favourable mRS at day 90 (0-2) was found in 91/119 patients available for FU (76%). ICH occured in 23 patients (19 with and 4 with symptoms). 8 patients had a worse clinical outcome at discharge than prior to the infarction. 6 (4.5%) patients died. <h3>Conclusion</h3> The final analysis shows a good safety profile and a high efficacy of APERIO® Stentretriever in distal occlusions. <h3>Disclosure of Interest</h3> yes this work was sponsored by Acandis.